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Neuromuscular junctionSarcopenia is a recently deﬁned medical condition described as age-associated loss of skeletal muscle mass
and function. Recently, a transgenic mouse model was described linking dispersal of the neuromuscular junc-
tion caused by elevated agrin degradation to the rapid onset of sarcopenia. These mice show a signiﬁcant el-
evation of serum levels of a C-terminal agrin fragment (CAF) compared to wild-type littermates. A series of
experiments was designed to ascertain the signiﬁcance of elevated agrin degradation in the development
of human sarcopenia. A quantitative Western blot method was devised to detect CAF in sera of humans. A
ﬁrst trial on consenting blood donors (n=169; age 19–74 years) detected CAF in the limited range of
2.76±0.95 ng/ml. In sarcopenia patients (diagnosed according to clinical and instrumental standards)
mean CAF levels were signiﬁcantly elevated (p=9.8E10-9; n=73; age 65–87 years) compared to aged
matched controls. Of all sarcopenia patients, 40% had elevated, non-overlapping CAF levels compared
to controls. Evidence is presented for a pathogenic role of the agrin/neurotrypsin system in a substantial
subset of sarcopenia patients. These patients are characterized by elevated CAF blood levels compared to
aged-matched healthy volunteers suggesting the identiﬁcation of an agrin-dependent form of sarcopenia.
Elevated CAF levels in a large subpopulation of sarcopenic patients suggest the existence of a speciﬁc
form of sarcopenia for which CAF could become a biomarker and a new target for therapeutic interven-
tions. The feasibility of this approach was demonstrated by the development of a small molecule capable
of inhibiting neurotrypsin in vitro and in vivo.
© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Sarcopenia, often referred to as age-related muscle wasting, is a
recently recognized and now exploding geriatric problem (Cruz-
Jentoft et al., 2010a), the cost of which in terms of both life expectan-
cy and medical expenses is imposing a heavy burden on the Western
Health Care systems (Abellan van Kan, 2009). The impact of sarcope-
nia on daily life is enormous; hallmarks of sarcopenia are frequent
falls, frailty, disability, and shortened life expectancy. Sarcopenia is
common in the elderly increasing with age and reaching a 50% inci-
dence peak at the age of 85 (Cruz-Jentoft et al., 2010b). With the in-
creasing life expectancy the incidence of sarcopenia patients is
expected to increase substantially in the near future.
There is high need for new biomarkers and effective treatments
for sarcopenia (Kimball et al., 2004). Presently, there is a consensus
that sarcopenia is a syndrome and may have multiple contributing
factors. Nutrition, life style, and hormonal or biochemical changes in+41 44 200 21 10.
rijbloed).
-NC-ND license.muscles particularly the ones affecting energy balance have been sug-
gested to cause sarcopenia (Cannon, 1995; Glass, 2003).
Recently, it has been reported that pre-synaptic expression of the
serine protease neurotrypsin in motoneurons produced a sarcopenia-
like phenotype in young adult mice (Butikofer et al., 2011). Many
post-synaptic and muscular alterations including fragmentation of
the neuromuscular junction (NMJ), a reduced number of muscle ﬁ-
bers, increased heterogeneity of ﬁber size, central nuclei, ﬁber-type
grouping, and an increased proportion of type I ﬁbers were observed.
It was suggested that the destabilization of the NMJ through proteo-
lytic cleavage of agrin was the onset of a pathogenic pathway ending
in sarcopenia. Agrin, a synaptically located protein (Misgeld et al.,
2005; Bezakova et al., 2001; Bezakova and Ruegg, 2003) is a key play-
er for and during initial formation and maintenance of NMJs by regu-
lating the molecular assembly of pre- and post-synaptic structures
including aggregates of acetylcholine receptor (AChR) (Bezakova
et al., 2001). Cleavage of agrin by neurotrypsin, thereby releasing a
soluble 22 kDa C-terminal agrin fragment (CAF) (Stephan et al.,
2008) leads to inactivation of agrin and consequently to a dispersal
of NMJs (Bolliger et al., 2010). Agrin stands at the beginning of a
sophisticated pathway which involves the rearrangement of the
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pression of key proteins to facilitate the functioning and maintenance
of the NMJ. A main issue of this pathway is the clustering and stabili-
zation of acetylcholine receptors at the NMJ. Binding to LRP-4 agrin
triggers the association with MuSK which transfers the signal inside
the muscle ﬁber. MuSK is being self-phosphorylated and the signaling
leads via DOK-7 and CRK to diverse activator kinases like Abl, Pak1
and others. Interestingly, the knock out mice of agrin, LRP-4, MuSK,
and DOK7 and the double knock out of CRK and CRK-L share the
same phenotype with sprouting of nerve terminals in the diaphragm
of mice (Lin et al., 2001; Weatherbee et al., 2006; DeChiara et al.,
1996; Okada et al., 2006; DeChiara et al., 1996; Hallock et al., 2010).
Also, the over-expression of neurotrypsin leads to the same pheno-
type (Bolliger et al., 2010).
This work for the ﬁrst time identiﬁes a substantial subgroup of sar-
copenia patients suffering from a clear pathogenic mechanism, name-
ly elevated agrin degradation. Agrin-dependent sarcopenia appears to
be distinguishable from natural muscle aging and shows a clear neu-
rogenic component. These studies demonstrate that not all sarcope-
nic patients have the same pathogenic mechanism supporting the
concept of multi-factoriality (Cruz-Jentoft et al., 2010b).2. Materials and methods
2.1. Generation of the human CAF speciﬁc monoclonal mouse antibody
28A6H11
Three 6–8 weeks old female Balb/c mice were immunized with
90–150 μg of a C-terminal human agrin fragment in complete
Freund's adjuvant with a standard 4 time boost protocol. Cells from
the knee lymph knots were prepared and the resulting B-cells were
fused with P3-X63-Ag8 mouse myeloma. Supernatants of mother
clones were screened by ELISA for positivity. Single clones were gen-
erated by a two fold limited dilution.2.2. Expression and puriﬁcation of the monoclonal antibody 28A6H11
Hybridoma cells were adapted to serum free ISF-1 medium (BIO-
CHROME AG) and grown for 5–7 days. Approximately 100 ml condi-
tioned medium was subjected to protein-G sepharose chromatography
and eluted with 100 mM citrate buffer pH 2.6.
Positive fractions were pooled and neutralized by an appropriate
amount of 2 M Tris. The puriﬁed antibody was dialysed against PBS
and biotinylated using a NHS biotinylation kit (PIERCE).2.3. Generation and keeping of SARCO mice
All experiments were performed on C57/Bl6 mice in accordance to
Swiss guidelines for proper conduct of animal experiments under su-
pervision of the local authorities. The transgenic human neurotrypsin
expressing mice (B6.C3-Tg(PRSS12) 491 Zbz), herein called SARCO
mice, are previously described by Stephan et al. (2008) and
Butikofer et al. (2011). Genotyping was done as described by
Stephan et al. (2008).2.4. Treatment schedule
5 adult mice were treated with 25 mg/kg NT-1474 in 20% DMSO
with PBS (10 ml/kg). As vehicle control another 5 mice were treated
with 10 ml/kg of 20% DMSO in PBS. Each mouse received three intra-
peritoneous injections with 8 hours interval between two injections.
5 h after the last injection the mice were euthanatized with CO2 and
CAF levels of the mice were determined with Western blot.2.5. Recombinant Agrin fragments and in vitro digestion of human agrin
CAFz0 and CAFz8 were produced and puriﬁed as described
(Matsumoto-Miyai et al., 2009) using constructs which allowed to
cleave off the n-terminal his tag using the prescission cleavage site di-
rectly after the tag. After puriﬁcation via IMAC, the tag was removed
by prescission cleavage. Full length human agrin and neurotrypsin
were produced and puriﬁed as described (Reif et al., 2008). Full
length agrin was incubated in 20 mM MOPS, 150 mM NaCl, 5 mM
CaCl2, 0.1% PEG, pH 7.5 with neurotrypsin at 37 °C for 2 h and, for a
complete digestion for 4 h. As negative control, agrin was incubated
without adding neurotrypsin. After digestion the samples were
mixed with Lämmli buffer and separated by SDS-PAGE. The gels
were stained with Sypro Ruby (Invitrogen) according to the manufac-
turer's standard protocol. Fluorescence imaging of protein bands was
done with a Stella imaging system (Raytest, Germany).
2.6. IC50 determination for human neurotrypsin
The neurotrypsin assay has been performed as described (Reif et
al., 2008). In brief, a compound dilution series in DMSO was made
and added to the neurotrypsin assays containing a 44 kDa C-
terminal agrin fragment (AgC44y0z0) containing the β-cleavage site
for neurotrypsin. The reaction was performed for 105 min at 37 °C
to ensure measurement at the initial part of the reaction. The reaction
was stopped by adding Lämmli buffer and the setups were separated
via SDS-PAGE. Quantiﬁcation of the product bands was made by sypro
ruby staining (Invitrogen) and ﬂuorescence determination of the
product bands in a Stella imaging system (Raytest).
2.7. Western blot
Human serum samples were stored frozen at −86 °C in 2-ml
screw-cap polypropylene tubes. Before use for Western blotting the
samples were tempered for 20 min at 37 °C, mixed by inverting
them 7 times and centrifuged for 3 min at 16,000×g.
Human serumwas diluted 1:20 with 1×Lämmli buffer and heated
for 5 min to 95 °C. Samples (10 μl) were loaded onto 4–12% NUPAGE
gels (Inivitrogen). Separated proteins were transferred to PVDF (Invi-
trogen) membranes by wet blotting for 60 min at 24 V. CAF contain-
ing fragments in human serum were detected using the biotinylated
monoclonal anti-CAF antibody 28A6H11 described above. As reporter
molecule, streptavidin-poly-HRP conjugate (PIERCE) was used. For
detection, Chem Glow West substrate (Alpha Innotech) was applied
and the chemiluminescence was recorded with a Stella imaging sys-
tem (Raytest, Germany). CAF concentration in human serum was de-
termined with a known amount of recombinant CAFz0 used as
calibrator.
CAF in blood from mice was detected as described above. Brieﬂy,
blood was collected by puncture of the lateral tail vein into serum
tubes (BD Microtainer) and 1:2 diluted with PBS. The mixture was ﬁl-
tered using 100 kDa cut-off centrifugal ﬁlters (Microcon) for 10 min.
The ﬂow through was collected and used for analysis by western
blot as described above. Murine CAF was detected using the afﬁnity
puriﬁed polyclonal antibody R139 (Bolliger et al., 2010) and goat
anti-rabbit peroxidase conjugate (Sigma Aldrich).
2.8. CAF elevation in SARCO mice
Recently, a mouse model has been reported that reproduces the
phenotypes of sarcopenia in humans (Butikofer et al., 2011). The het-
erozygous mice (SARCO mice) over-express human neurotrypsin
under the thy1-2 promoter leading to elevated agrin degradation
and a clearly abnormal neuromuscular phenotype. This prompted us
to further investigate the link between elevated neurotrypsin activity
and the development of sarcopenia in humans, starting from
Fig. 1. Scatter diagram of CAF serum levels plotted against age of female (○, n=86)
and male (▲, n=83) blood donors. Serum CAF levels are in a narrow range in a healthy
population.
Table 1
Characteristics of the analyzed groups. BD: blood donor group; AMC: age matched con-
trol group; and SP: sarcopenic patients group.
Group Gender n CAF Age
(ng/ml) (years)
BD Both 169 2.76±0.95 46.5±15.0
Male 83 2.80±0.84 49.6±14.6
Female 86 2.72±1.04 43.4±14.9
AMC Both 60 2.64±0.97 71.2±5.6
Male 32 2.90±1.09 73.2±6.7
Female 28 2.34±0.72 69.0±2.7
SP Both 73 4.71±2.60 70.8±5.5
Male 39 5.17±2.79 71.6±5.9
Female 34 4.18±2.30 69.8±4.9
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(CAF) that results from agrin cleavage by neurotrypsin at the beta
site, as a marker of neurotrypsin activity and/or agrin degradation.
This fragment is known to be crucial for the formation of a NMJ. Ele-
vated neurotrypsin activity should result in increased agrin cleavage
fragments in general, thus also in increased CAF levels. Elevated
agrin degradation is documented in the brain of the neurotrypsin
overexpressing mice. However, we developed a method to detect
CAF in blood of mice. Indeed, using the above described Western
Blot it was possible to detect CAF in both WT littermates and SARCO
mice, the latter demonstrating a CAF elevation of approximately 50%
compared to the WT (Suppl. Fig. 1). On the contrary, CAF was not de-
tectable in neurotrypsin-deﬁcient mice a fact that strengthens the
role of CAF as a marker of the neurotrypsin/agrin system's activity.
2.9. Neurotrypsin cleavage of agrin
To test if agrin cleavage fragments are detectable also in human
blood, we investigated in vitro all the possible agrin cleavage frag-
ments which result from neurotrypsin digestions (Suppl. Fig. 2). Neu-
rotrypsin can cleave agrin at two sites, the α-site and the β-site (Reif
et al., 2007). The α-site is situated between the ﬁrst serine/threonine
rich segment and the SEA domain, while the β-site is in front of the
LG3 domain. Thus, cleavage of agrin by neurotrypsin results in the
generation of several agrin fragments. Full length agrin has a protein
core size of roughly 215 kDa but runs spread due to its high glycan
content above 250 kDa. Complete digestion of agrin (Suppl. Fig. 3 A)
results in the generation of an N-terminal agrin fragment (NAF)
with a protein core size of about 115 kDa. Due to the high glycan con-
tent, it migrates between 150 and 250 kDa in the SDS-gel. By cleavage
at the α and β-sites, a middle agrin fragment (MAF) of approximately
80 kDa – depending on the amino acid insertions in the x- and y
sites – is generated. It migrates at about 90 kDa in the SDS-gel. Cleav-
age at the β-site generates CAF (C-terminal agrin fragment) with a
molecularweight of 20–22 kDa, dependingon the amino acid insertions
at the z-site. CAF without any insertion runs at about 22 kDa in an
SDS-gel.
Incomplete digestion of agrin with neurotrypsin (Suppl. Fig. 3 B)
reveals fragments which are produced if neurotrypsin cleaves only
at the α-site or at the β-site. Besides the NAF, MAF and CAF which
result from the complete digestion one can observe in addition a
C-terminal fragment migrating at about 110 kDa in the gel. This
large C-terminal agrin fragment is called AgC110 herein. A large
N-terminal fragment of agrin (AgN200) which results by cleavage
only at the β-site with a molecular weight of 197–200 kDa size cannot
be resolved by SDS gel electrophoresis because it overlaps with the
residual full length protein.
Using the CAF speciﬁc monoclonal antibody 28A6H11, CAF and
AgC110 can be simply detected in human serum (Suppl. Fig. 3 C).
Full length agrin was not detectable in serum using this antibody. In
addition, we were unable to detect the agrin fragments MAF or
AgN200 with the polyclonal R132 antibody (Reif et al., 2007) in
human sera. For further studies we then decided to focus on the
quantiﬁcation of CAF, since this fragment is virtually unable to elicit
the acetylcholine clustering activity (Bezakova and Ruegg, 2003).
2.10. Normal values for CAF
To substantiate the initial ﬁnding that CAF can be measured in
human serum and to deﬁne the range of normal levels in ostensibly
healthy people a control group of 169 consenting Swiss blood donors
(BD) from the Zurich area (86 women and 83 men, age 19 to
74 years) was tested for serum CAF levels by Western blotting
(Fig. 1). Each sample was measured in duplicate. Over the whole
blood donor population CAF levels are in a relatively narrow range
of 2.76±0.95 ng/ml. Using the average value±2 SD, the normalCAF range falls between 0.86 and 4.66 ng/ml. Of the 6 outliers, one
is below the lower limit and 5 are above the upper limit, 4 of these
last are older than 50.
2.11. Gender and age dependency of CAF
The males' mean (±SD) CAF level is 2.80±0.84 ng/ml compared
to the mean of the whole study population (2.76±0.95 ng/ml) and
2.72±1.04 ng/ml for females (Table 1) with no signiﬁcant gender dif-
ference. Due to the age dependency of sarcopenia, we examined
whether CAF values vary with age by comparing mean CAF values
for each decade represented in the study population (Fig. 2;
Table 2). CAF shows the lowest mean value of 2.33±0.69 ng/ml in
the youngest group (19–29 y o.) which is also the only group signiﬁ-
cantly different from the 30–39 y o. (p=0.045), 60–69 y o.
(p=0.0004) and 70–74 y o. (p=0.0014) groups. No signiﬁcant gen-
der difference is observed in each age group (data not shown). In con-
clusion, there is a signiﬁcant 15% lower CAF level in young adulthood
compared to the mid age groups and slightly higher CAF in people
older than 60 (approximately 10% higher than the mid age groups).
2.12. Study populations
A multi-center, non-randomized, open-label, clinical study was
designed. After approval from an independent Bioethics Committee
at Bangalore, the Institutional Review Boards (IRB) of participating
sites and the Indian regulatory authorities, study participants were
recruited from geriatric hospitals in Bangalore, Hyderabad and Kalk-
ota, India. Prospective study participants were informed orally and
in written form about the purpose of the study and its procedures.
After signature of the informed consent, candidates underwent a
Fig. 2. Box plot representing CAF levels of the BD group categorized by different de-
cades. Boxes are limited by the lower and upper quartiles and the whiskers deﬁne
the range from 5% to 95% of the data sets. The solid lines in the boxes represent the me-
dian value. The numbers of samples of each decade are depicted in the boxes. The CAF
level is constant over a wide life span in humans.
72 S. Hettwer et al. / Experimental Gerontology 48 (2013) 69–75preliminary medical screening which included assessment of age
(older than 65 years), grip strength, knee strength and a question-
naire regarding performance of daily living and history of falls.
Study candidates suffering from co-morbidities such as diabetes,
COPD, renal difﬁculties, osteoporosis and other medical ailments
were excluded from the study. For the assessment of grip strength
and knee strength the corresponding baseline values published by
Park et al. (2007) were used. Assessment of eligibility was done by
previously trained local physicians at each hospital.
Out of 750 screened subjects, 350 were eligible for a secondary
screening which included dual-energy X-ray absorptiometry (DEXA)
of the appendicular skeletal muscle mass (ASMM). On the basis of
the published baseline value (Visser et al., 2003) the candidates
were divided into the age matched control (AMC) or the sarcopenia
patient (SP) group. This latter was formed by subjects with an
ASMM smaller than 20%. It was ensured that both sexes were equally
represented in the two groups. Study participants older than 65 years
were separated into the ﬁnal aged matched control (AMC, aged from
65 to 88 years) and sarcopenia patient (SP) groups according to ac-
cepted standardized diagnostic tools (Cruz-Jentoft et al., 2010a). In-
clusion criteria for the SP group were DEXA scan values below −1
(SD). People with DEXA values between −1 and 0 were distributed
to the SP or AMC groups based on their grip strength, knee strength
and reported difﬁculties in daily living as frequent falls, difﬁcultiesTable 2
BD group divided into decades.
Age group Gender n CAF (ng/ml)
19–29 y Both 26 2.33±0.69
Male 6 2.37±0.66
Female 20 2.23±0.71
30–39 y Both 28 2.76±0.84
Male 13 2.88±1.10
Female 15 2.65±0.55
40–49 y Both 30 2.61±0.93
Male 15 2.74±0.91
Female 15 2.48±0.96
50–59 y Both 26 2.80±1.42
Male 12 2.48±0.74
Female 14 3.06±1.80
60–69 y Both 46 3.02±0.86
Male 26 2.97±0.85
Female 20 3.09±0.88
70–74 y Both 13 2.97±0.45
Male 11 2.94±0.48
Female 2 3.10±0.25in walking and lifting objects. People with DEXA values >0 were
assigned to the AMC group. The ﬁnal SP group comprised 73 subjects
(34 women and 39 men, ages 65 to 87), and the AMC group com-
prised 60 subjects (28 women and 32 men, ages 65 to 88 years).
The study started at the end of May, 2008, and terminated at the be-
ginning of March, 2010. A study ﬂow chart is presented in the supple-
mentary online material (Suppl. Fig. 4).
As reference for a healthy population, in a separate study, blood
was obtained from healthy Swiss blood donors after written consent.
This independent control group (BD) included 169 subjects (86
women and 83 men, ages 19 to 74 years).
2.13. Anthropometric data acquisition
The study participants' total body mass was determined by scale
and their body height was measured by a standard stadiometer.
Body mass index (BMI) was calculated as total body mass in kg di-
vided by the square of body height expressed in meters. According
to their BMI women were categorized as underweight (b19.1 kg/
m2), normal (19.1–25.8 kg/m2), or overweight (>25.8 kg/m2) and
men as underweight (b20.7 kg/m2), normal (20.7–26.4 kg/m2) or
overweight (>26.4 kg/m2). Threshold data were taken from the Sec-
ond National Health and Nutrition Examination Survey, (NHANES II)
1976–80.
2.14. Grip and knee strength
Grip and knee strengths were used as indicators of muscle
strength (Visser et al., 2003). Grip strength was measured with an
isometric Jaymar dynamometer from JLW Instruments, Chicago.
Knee strength, i.e. maximal isokinetic strength of knee extensors,
was assessed by a Kin-Com 125 AP dynamometer (Chattanooga, TN).
2.15. Statistical analysis
Data were statistically analyzed with the Student's t-test and using
the free statistic tool R (version 2.9.0). The data set used contained
the variables age, sex, group (BD, SP or AMC), DEXA, height, weight,
BMI, grip strength, knee strength and CAF value.
Characteristics of participant groups or subsets thereof are shown
as box plots delimited by the lower and upper quartile with whiskers
representing the range from 5% to 95% of the data sets. Numbers of
participants are depicted in the boxes. Signiﬁcant differences of the
mean values (Student's t-test; pb0.05) are marked by asterisks.
Values in tables and text are mean values with accompanying stan-
dard deviation. Scatter plots between CAF concentration and age are
shown for the BD group for both sexes and for the AMC and SP
groups.
3. Results
3.1. Design of sarcopenia study
To evaluate the relevance of an enhanced neurotrypsin activity in
the development of sarcopenia in humans a clinical study was
designed. In total, 73 sarcopenia patients (SP) were identiﬁed by the
screening method. Another group of 60 people without the indication
of sarcopenia served as age matched controls (AMC).
It was made sure that both groups, AMC and SP did not differ in
BMI. Also, in the used set of individuals there were no gender speciﬁc
differences in BMI. For the AMC group, the average BMI was 22.3±
2.4 kg/m2 and for the SP group 22.0±3.8 kg/m2 (Suppl. Fig. 5).
DEXA scan results were one of the most stringent selection criteria
for the grouping of individuals into the AMC or SP group. Thus, the SP
group had signiﬁcantly lower DEXA t-scores (−1.8±1.1) than the
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ference within both groups.
Grip strength measurement revealed signiﬁcantly weaker grip
strength of the females in the SP group compared to the AMC
group. The males in the AMC group showed a large heterogeneity in
grip strength (24.1±6.8 kg). Therefore, no signiﬁcant difference to
males of the SP group (20.7±3.9 kg) was observed, although the
mean values are clearly lower in the SP group.
In addition, knee strength was found to be signiﬁcantly different
between the AMC group (525.6±102.7 N) and the SP group (412.8±
134.4 N). There was no gender speciﬁc effect in the AMC group while
a signiﬁcant difference was observed in the SP group between males
and females (p=0.0013).Fig. 4. The CAF level in sarcopenia patients is signiﬁcantly elevated compared to the BD
and AMC groups. Box plot representing CAF levels of the BD, AMC and SP groups. Boxes
give the lower and upper quartiles and the whiskers deﬁne the range from 5% to 95% of
the data sets. The solid lines in the boxes represent the median value. The numbers of
samples of each group are depicted in the boxes. BD: blood donor group; AMC: age
matched control group; and SP: sarcopenic patients group.3.2. CAF levels in the sarcopenia study
CAF levels of both SP and AMC groups were determined with
Western blot. The CAF values from the SP respectively AMC group
ranged from 1.51 to 16.68 ng/ml resp. 0.94–6.10 ng/ml. The average
CAF level of the SP group was 4.71±2.60 ng/ml. The average of the
AMC group was 2.64±0.97 ng/ml (Table 1; Fig. 3). This means that
the average CAF level of the SP group is highly signiﬁcantly elevated
compared to the age matched control group AMC (p≪0.00001). In
total, 38% of the SP group (28 out of 73) was above the upper thresh-
old of 4.66 ng/ml as determined by measurement of the blood donor
group, whereas in the AMC group, only 4 out of 60 (7%) were above
this cut-off level. There is no obvious tendency among the AMC
group for an increase of CAF levels with age. In the SP group however,
there is a slight tendency for age-associated elevated CAF levels. In
this group, the standard deviation was larger than in both other con-
trol groups (Fig. 4). The average CAF value of the AMC group is indis-
tinguishable from the blood donor group.
CAF values only slightly differ for the genders in all study groups
(Suppl. Fig. 6). For the blood donor group the average CAF values
were 2.72±1.04 ng/ml for females and 2.80±0.84 ng/ml for males
(not signiﬁcant). The values for the age matched control group were
slightly lower with 2.34±0.72 ng/ml for females and 2.90±
1.09 ng/ml for males. In this case one can observe a signiﬁcant differ-
ence (p=0.03). The mean CAF levels for both genders of the sarcope-
nia patients group were signiﬁcantly higher with 4.18±2.30 ng/ml
for females and 5.17±2.79 ng/ml for males. In this group, the stan-
dard deviation was larger than in both other control groups with no
signiﬁcant gender difference.Fig. 3. Scatter plot of CAF serum levels of age matched controls (AMC, ○, n=60) and
sarcopenia patients (SP, ▲, n=73). Serum CAF levels of sarcopenia patients are elevat-
ed compared to an age matched control group.3.3. Development of a small molecule inhibitor
To assess the potential therapeutic intervention we focussed on
the protection of agrin from proteoloytic degradation by neurotryp-
sin. For this we aimed to inhibit neurotrypsin thus protecting agrin's
NMJ stabilizing function.
Neurotrypsin is a serine protease but a broad set of known serine
protease inhibitors like benzamidine, PMSF, AEBSF, TLCK, aprotinin
and leupeptin did not show inhibition of neurotrypsin. It was con-
cluded that neurotrypsin is a very speciﬁc protease with a unique
substrate binding pocket (Reif et al., 2007). However, a set of lead
compounds was identiﬁed after screening of a focussed compound li-
brary. The neurotrypsin inhibition of these initial compounds was fur-
ther improved by chemical modiﬁcations using a homology model of
neurotrypsin. The ﬁnal compound NT-1474 was shown to be the best
neurotrypsin inhibitor reported so far with an IC50 of 570 nM for
human neurotrypsin. Treatment of mice with this compound led to
a reduction of CAF in murine serum and showed its potency in vivo.
After a 3 step dosing with 25 mg/kg NT-1474 within one day the
CAF level in serum was reduced by 44% compared to vehicle treated
littermates (Fig. 7).
4. Discussion
We have focused our work on the identiﬁcation and quantiﬁcation
of CAF. This agrin fragment consists basically of the LG3 domain of
agrin, which is known to play an essential role in NMJ formation
(Bezakova and Ruegg, 2003). CAF itself is not active but absolutely re-
quired for NMJ formation. This work clearly identiﬁes CAF as a pro-
teolytic breakdown product of agrin by neurotrypsin. Agrin cleavage
at the β-site, inactivates NMJ formation. Currently, neurotrypsin is
the sole protease known to generate the agrin fragments CAF and
AgC110, as neurotrypsin knock out mice do not contain CAF or
AgC110 in blood or tissues (Stephan et al., 2008). Moreover, an in-
creased activity of neurotrypsin in motor neurons led to an increase
in CAF blood levels, notably the AgC110 level was not elevated in
blood of these mice (unpublished results). In human sera, the same
agrin fragments, CAF and AgC110 are detected. They are identical to
the ones in mice and are likely to originate from neurotrypsin as
well. Finding CAF absence in humans lacking neurotrypsin would
bring additional evidence that neurotrypsin is the only source of
CAF. Unfortunately, a family with a frameshift mutation in the neuro-
trypsin gene, leading to an effective neurotrypsin knock out (Molinari
et al., 2002) could not be tested for CAF levels.
Fig. 5. The CAF levels in the blood donor and age matched control groups lie in a narrow range. Distribution diagrams of CAF levels in 0.5 ng/ml steps of the different study groups. A:
BD, B: AMC, C: SP and D: all groups. BD: blood donor group; AMC: age matched control group; and SP: sarcopenic patients group.
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donors lies in a narrow range from 0.86 to 4.66 ng/ml and 96.5% of all
measured CAF values are found in this range. Thus, the production of
CAF seems to be tightly regulated.
Although no longitudinal CAF studies exist, the detected CAF
levels in the different age groups of blood donors suggest a slight in-
crease of CAF over life time. Interestingly, the lowest mean CAF levels
are detected in young adult people and the highest mean values are
measured in the population older than 60 years.Fig. 6. Box plot representing CAF levels of the BD, AMC and SP groups. The SP group was
splitted into a normal level group and a high level group containing all values above the
upper threshold of 4.66 ng/ml. Boxes are delimited by the lower and upper quartiles
and the whiskers deﬁne the range from 5% to 95% of the data sets. The solid lines in
the boxes represent the median value. The numbers of samples of each group are
depicted in the boxes. BD: blood donor group; AMC: age matched control group; and
SP: sarcopenic patients group.Using common parameters like DEXA scan, grip strength and knee
strength for the separation of sarcopenia patients from the control
group seem to be an overall good strategy. Nevertheless, it is difﬁcult
to get clearly separated groups in respect to all parameters at once.
People with low DEXA values can have a high grip or knee strength
and vice versa. Thus, the current criteria are not very stringent yet. In-
terestingly, there seems to be a large variation of strength parameters
especially in the male population.
CAF levels in all groups follow a Gaussian distribution (Fig. 5). The
BD group shows a mean CAF value of 2.76±0.95 ng/ml (from 0.86 to
4.66 ng/ml i.e. the ±2SD range). The AMC group is almost identical to
the BD group (CAF 2.64±0.97 ng/ml). No value is below the lower
threshold of 0.86 ng/ml and 4 values are above the upper threshold
of 4.66 ng/ml.
The SP group is clearly different from the BD and AMC groups. The
mean CAF value is signiﬁcantly elevated and the standard deviation is
much larger (4.71±2.60 ng/ml). No value is below the lower thresh-
old and 28 out of 73 (38%) are above the upper threshold. The mean
CAF level of all values that lie within the normal range is 3.24±
0.88 ng/ml. This is almost identical to the corresponding age group
in the BD study. Taking into account only values which are above
the upper threshold of 4.66 ng/ml the mean CAF value is 7.01±
2.80 ng/ml (Fig. 6).
This group of sarcopenia patients are potentially affected by an
over-activity of neurotrypsin which leads to NMJ destruction with
subsequent loss of muscle mass and function. This group may suffer
from agrin dependent sarcopenia while the others may suffer from
sarcopenia caused by other reasons like malnutrition, hormonal im-
balance, inactivity or other pathophysiological backgrounds.
The mean CAF values of the AMC group are slightly below the
values for the blood donor group, although statistically not signiﬁ-
cant. Individuals from this group were older than 65 years and there
was no trend to higher CAF values with increasing age. The reason
Fig. 7. Structure, IC50 determination and in vivo administration of NT-1474. The struc-
ture of the compound is given in the graph, R1 is a heterocycle and R2 is a halogen. The
IC50 for neurotrypsin was determined to be 570 nM. Insert the compound was admin-
istered intraperitoneal in WT mice and CAF levels were determined by Western blot-
ting. The compound reduces the CAF concentration in blood by more than 40%. V:
vehicle control; and 1474: NT-1474 treated mice.
75S. Hettwer et al. / Experimental Gerontology 48 (2013) 69–75for the lower CAF value can be that the samples from the blood donor
group are arbitrarily chosen from the population and one can expect
pre-frail people among the selection or people with early develop-
mental stages of sarcopenia although they were regarded as healthy
for the donation of blood. In contrast, people from the AMC group
were especially selected not to be sarcopenic, which will exclude peo-
ple suffering from frailty or other muscular diseases. In view of a pos-
sible connection of the degree of frailty or sarcopenia with increasing
CAF levels, the lower levels in the AMC group clearly make sense.
The signiﬁcant difference in CAF levels betweenmales and females
in the AMC group is somewhat surprising but may reﬂect different
hormonal or physical states in elderly men and women. However,
no gender speciﬁc difference in the CAF level of the blood donor
group was observed.
As mentioned above, there is a high need for biomarkers in sarco-
penia (Kimball et al., 2004). This work for the ﬁrst time identiﬁes a
substantial subgroup of sarcopenia patients suffering from a clear
pathogenic mechanism, namely elevated agrin degradation. Agrin is
a key protein in the development and homeostasis of the neuromus-
cular junction (Bezakova and Ruegg, 2003). Agrin-dependent sarco-
penia appears to be distinguishable from natural muscle aging and
shows a clear neurogenic component. These studies demonstrate
that not all sarcopenia patients have the same pathogenic mechanism
supporting the concept of multi-factoriality (Cruz-Jentoft et al.,
2010b).
Our ﬁndings open new avenues for speciﬁc treatment approaches
and have a substantial impact on clinical trial design, treatment of
sarcopenia, and monitoring treatment effects. Currently, many re-
searches and geriatricians consider sarcopenia as a sole muscle weak-
ness problem (Borst, 2004). In fact, the true causative problem could
be loss of synapses and in this respect sarcopenia bears some similar-
ity to Alzheimer's Disease (Burns et al., 2010).
A promising treatment strategy with the new compound NT-1474
was developed. This compound is able to speciﬁcally inhibit neuro-
trypsin. As CAF levels are a direct measure for neurotrypsin activity,
it could be shown that this compound is active in vivo in mice. Future
work aims at demonstrating that inhibition of neurotrypsin will
reduce the NMJ destabilizing forces in the neuro-muscular system,
thus leading to better muscle maintenance and function.
Supplementary data to this article can be found online at doi:10.
1016/j.exger.2012.03.002.References
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